The Childhood Cancer Caucus applauds Dr. Harold Varmus, the Director of the National Cancer Institute (NCI), for announcing the appointment of Dr. Greg Aune, a pediatric hematologist-oncologist from The University of Texas Health Science Center at San Antonio, to NCI's Council of Research Advocates.
On September 30th, the U.S. Food and Drug Administration announced it has awarded 15 grants totaling more than $19 million to boost the development of medical device, drug, and biological products for patients with rare diseases, with at least a quarter of the funding going to studies focused solely on pediatrics. $1.6 million will go toward a Phase 2 Study of Poly-ICLC for the Treatment of Pediatric Low Grade Gliomas, the most common type of brain tumor in children.
On September 19, Dr. Francis Collins, the Director of the National Institutes of Health (NIH), announced a new pediatric trial for children with cancer. Sponsored by the National Cancer Institute (NCI), the Molecular Analysis for Therapy Choice Program (MATCH) trial will enroll children with advanced cancers that have progressed on standard therapy.
On Friday, September 19, the Childhood Cancer Caucus will host its 5th Annual Childhood Cancer Summit: "Pediatric Cancer: Major Advances, Major Challenges".
Representatives McCaul and Van Hollen send letters to the FDA and Teva Pharmacueticals to seek more information about the ongoing shortage of daunorubicin, an essential therapy in the treatment of leukemia in children.
Progress into research and development of the first new pediatric cancer drugs in nearly 30 years was announced at the 4th Annual Congressional Childhood Cancer Summit on Capitol Hill on September 19, 2013.
Leaders from NCI and FDA address the third annual Childhood Cancer Summit to discuss federal efforts to combat childhood cancers.
This month, we pay tribute to the families, friends, professionals, and communities who lend their strength to children fighting pediatric cancer.
Incentivizes Drug Companies to Develop New Treatments for Children with Rare Pediatric Diseases
Congresswoman Jackie Speier (D-CA) and Congressman Michael McCaul (R-TX) introduce bipartisan legislation to improve and advance the treatment of childhood cancer survivors.
The Childhood Cancer Caucus applauds Dr. Harold Varmus, the Director of the National Cancer Institute (NCI), for announcing the appointment of Dr. Greg Aune, a pediatric hematologist-oncologist from The University of Texas Health Science Center at San Antonio, to NCI's Council of Research Advocates.
On September 30th, the U.S. Food and Drug Administration announced it has awarded 15 grants totaling more than $19 million to boost the development of medical device, drug, and biological products for patients with rare diseases, with at least a quarter of the funding going to studies focused solely on pediatrics. $1.6 million will go toward a Phase 2 Study of Poly-ICLC for the Treatment of Pediatric Low Grade Gliomas, the most common type of brain tumor in children.
On September 19, Dr. Francis Collins, the Director of the National Institutes of Health (NIH), announced a new pediatric trial for children with cancer. Sponsored by the National Cancer Institute (NCI), the Molecular Analysis for Therapy Choice Program (MATCH) trial will enroll children with advanced cancers that have progressed on standard therapy.
